Vaxcyte, Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Vaxcyte reported positive topline results from OPUS-1, a Phase 3 trial of VAX-31 (31-valent pneumococcal conjugate vaccine) in 4,047 adults. VAX-31 met all prespecified co-primary immunogenicity endpoints across age groups (50+, 18-49), demonstrating noninferiority on 28 shared serotypes vs. PCV20/PCV21, superiority on 3 unique serotypes, and comparable safety. The company expects to submit a BLA (Biologics License Application) in 1H 2028, pending results from OPUS-2 and OPUS-3 trials (anticipated 1H 2027).
Why this rating
OPUS-1 success de-risks VAX-31's path to regulatory approval and potential market entry in a ~$12B pneumococcal vaccine market. For a ~$3.7B market-cap company, successful Phase 3 data for a lead candidate with broad coverage advantage is a major value inflection, though regulatory and commercial execution risks remain.
Price action (we called it positive)
before filing · preread $88.30 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.